Elicio Therapeutics (NASDAQ:ELTX) Price Target Raised to $23.00

Posted by Brenda Bartman on Jun 15th, 2026

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) had its price objective lifted by equities researchers at HC Wainwright from $17.00 to $23.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 54.88% from the company’s current price.

Other research analysts have also issued reports about the company. Rodman & Renshaw raised Elicio Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Elicio Therapeutics in a report on Friday, April 24th. LADENBURG THALM/SH SH started coverage on Elicio Therapeutics in a report on Wednesday, April 15th. They set a “buy” rating and a $20.00 price target on the stock. B. Riley Financial started coverage on Elicio Therapeutics in a report on Wednesday, June 10th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Wall Street Zen lowered Elicio Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Elicio Therapeutics has an average rating of “Moderate Buy” and an average price target of $21.75.

Check Out Our Latest Research Report on ELTX

Elicio Therapeutics Stock Performance

Shares of ELTX opened at $14.85 on Monday. The business’s fifty day moving average price is $11.36 and its 200 day moving average price is $9.96. Elicio Therapeutics has a 12-month low of $7.37 and a 12-month high of $16.00. The stock has a market capitalization of $283.43 million, a PE ratio of -6.19 and a beta of 1.13. The company has a debt-to-equity ratio of 5.75, a current ratio of 2.24 and a quick ratio of 2.24.

Elicio Therapeutics (NASDAQ:ELTX – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.16). Equities research analysts forecast that Elicio Therapeutics will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Elicio Therapeutics

Institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in shares of Elicio Therapeutics by 186.8% during the 3rd quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock worth $39,000 after purchasing an additional 2,335 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Elicio Therapeutics during the 2nd quarter worth about $46,000. Summit Financial LLC purchased a new stake in shares of Elicio Therapeutics during the 4th quarter worth about $80,000. HB Wealth Management LLC purchased a new stake in shares of Elicio Therapeutics during the 1st quarter worth about $112,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Elicio Therapeutics during the 4th quarter worth about $89,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Elicio Therapeutics

(Get Free Report)

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.